The effect of lithium on methamphetamine-induced regional Fos protein expression in the rat brain

NeuroReport

Volumn 10, Issue 5, 1999, Pages 895-900

  Lee, Youmei ^a   Hamamura, Takashi ^a   Ohashi, Kazuyo ^a   Fujiwara, Yutaka ^b   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Takaoka Hospital   (Japan)

Author keywords

Amygdala; Caudate putamen; Fos; Lithium; Manic state; Methamphetamine; Mood stabilizer; Nucleus accumbens; Prefrontal cortex

Indexed keywords

LITHIUM CHLORIDE; METHAMPHETAMINE; PROTEIN C FOS;

AMYGDALOID NUCLEUS; ANIMAL MODEL; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; IMMUNOREACTIVITY; LITHIUM BLOOD LEVEL; MALE; MANIA; NEUROBIOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; ORAL DRUG ADMINISTRATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT; WEIGHT GAIN;

EID: 0033528779     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199904060-00001     Document Type: Article

References (26)

1. Manji HK, Potter WZ and Lenox RH. Arch Gen Psychiatry 52, 531-543 (1995).
2. Brauer LH and de Wit H. Pharmacol Biochem Behav 56, 265-272 (1997).
3. Smith RC and Davis JM. Psychopharmacology 53, 1-12 (1977).
4. Robbins TW and Sahakian BJ. Animal models of mania In: Belmaker RH and van Praag HM, eds, Mania: An Evolving Concept. New York: Medical and Scientific Books, 1980: 143-216.
5. Van Kammen DP and Murpy DL. Psychopharmacologia 44, 215-224 (1975).
6. Van Kammen DP, Docherty JP, Marder SR et al. Psychopharmacology 87, 215-224 (1985).
7. Morgan JI and Curran T. Annu Rev Neurosci 14, 421-451 (1991).
8. Hamamura T, Lee Y, Fujiwara Y and Kuroda S, Brain Res 759, 156-159 (1997).
9. Paxinos G and Watson C. The rat brain in stereotaxic coordinates (2edn). Sydney: Academic Press, 1986.
10. Amdisen A. Clin Pharmacokinet 2, 73-92 (1977).
11. Graybiel AM, Moratalla R and Robertson HA. Proc Natl Acad Sci USA 87, 6912-6916 (1990).
12. Mathé AA, Miller JC and Stenfors C. Prog Neuro-Psychopharmacol Biol Psychiat 19, 1177-1187 (1995).
13. Miller JC and Mathé AA. Neuropsychopharmacology, 16, 408-418 (1997).
14. Robbins TW and Everitt BJ. Curr Opin Neurobiol 6, 228-236 (1996).
15. Alheid GF and Helmer L. Prog Brain Res 107, 461-484 (1996).
16. Robertson HA, Peterson MR, Murphy K and Robertson GS. Brain Res 503, 346-349 (1989).
17. Baptista T, Teneud, Contreras Q et al. J Neural Transm Gen Sect 94, 75-89 (1993).
18. Carli M, Anand-Srivastava MB, Molina-Holgado E et al Neurochem Int 24, 13-22 (1994).
19. Hérve D, Levi-Straus M, Marey-Semper I et al. J Neurosci 13, 2237-2248 (1993).
20. Bing G, Stone EA, Zhang Y and Filer D. Brain Res 592, 57-62 (1992).
21. Gross G, Dodt C and Hanft G. Naunyn Schmiedeberg Arch Pharmacol 337, 267-272 (1988).
22. Maggi A and Enna SJ. J Neurochem 34, 888-892 (1980).
23. Avissar S, Schreiber G, Danon A and Belmaker RH. Nature 331, 440-442 (1988).
24. Masana MI, Bitran JA, Hsiao JK et al. Brain Res 538, 333-336 (1991).
25. Lewander T. Effects of amphetamine in animals. In: Martin WR, eds. Drug Addiction, 2 edn, Berlin: Springer, 1977; 53-56.
26. Leslie RA, Moorman JM and Grahame-Smith JM. NeuroReport 5, 241-244 (1993).